Emerging therapies, such as daratumumab (anti-CD38 monoclonal antibody), have shown promise in AL amyloidosis when added to standard regimens (e.g., Dara-VCD), improving hematologic response and survival [16]. The gene discussed is CD38; the disease is AL amyloidosis.